Corrigendum to: Menopausal hormone therapy for primary prevention: why the USPSTF is wrong (Climacteric, (2017), 20, 5, (402-413), 10.1080/13697137.2017.1362156);Menopausal hormone therapy for primary prevention: why the USPSTF is wrong

Climacteric

Volumn 20, Issue 5, 2017, Pages 402-413

  Langer, R D ^a   Simon, J A ^b   Pines, A ^c   Lobo, R A ^d   Hodis, H N ^e   Pickar, J H ^d   Archer, D F ^f   Sarrel, P M ^g   Utian, W H ^h  

^a UNIVERSITY OF NEVADA   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

^d Department of Medicine   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

breast cancer; cardiovascular disease; chronic disease prevention; fragility fracture; hormone replacement therapy; Menopause; osteoporosis

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE;

ALL CAUSE MORTALITY; ARTICLE; BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; COLORECTAL CANCER; DEMENTIA; DIABETES MELLITUS; EVIDENCE BASED PRACTICE; FEMALE; FRAGILITY FRACTURE; HEART INFARCTION; HIP FRACTURE; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; MENOPAUSE; NONHUMAN; OBSTETRIC DELIVERY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; THROMBOEMBOLISM; URINE INCONTINENCE; BREAST TUMOR; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; ESTROGEN THERAPY; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; POSTMENOPAUSE; PROCEDURES; TIME FACTOR; UNITED STATES; WOMEN'S HEALTH;

BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE ACETATE; MENOPAUSE; MIDDLE AGED; POSTMENOPAUSE; PRIMARY PREVENTION; RISK FACTORS; TIME FACTORS; UNITED STATES; WOMEN'S HEALTH;

EID: 85028566321     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697137.2017.1368915     Document Type: Erratum

References (103)

1. Baber RJ, Panay N, Fenton A., IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016;19:109–50
2. North American Menopause Society. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 2017;24:728–55
3. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM., Estrogen replacement therapy. II. A prospective study in the relationship between carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979;54:74–9
4. Stampfer MJ, Willett WC, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;313:1044–9
5. Petitti DB, Perlman JA, Sidney S., Noncontraceptive estrogens and mortality: long-term follow-up of women in the Walnut Creek Study. Obstet Gynecol 1987;70:289–93
6. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75:1102–9
7. Paganini-Hill A, Ross RK, Henderson BE., Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ 1988;297:519–22
8. Falkeborn M, Persson I, Adami HO, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestin replacement. Br J Obstet Gynaecol 1992;99:821–8
9. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/progestin Interventions (PEPI) Trial. JAMA 1995;273:199–208
10. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933–41
11. Institute of Medicine, Thaul S, Hotra D, eds. An Assessment of the NIH Women’s Health Initiative. Washington, DC: The National Academies Press; 1993
12. Women’s Health Initiative Protocol. 1994. Available from: https://web.njit.edu/$wguo/Math654_2013/WHI_protocol.pdf
13. Lobo RA., Hormone-replacement therapy: current thinking. Nature Rev Endocrinol 2017;13:220–31
14. Langer RD, Manson JE, Allison MA., Have we come full circle: or moved forward? The Women’s Health Initiative 10 years on. Climacteric 2012;15:206–12
15. Hodis HN, Mack WJ, Henderson VW, et al. for the ELITE Research Group. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med 2016;374:1221–31
16. Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 1990;10:1051–7
17. Wagner JD, Martino MA, Jayo MJ, et al. The effects of hormone replacement therapy on carbohydrate metabolism and cardiovascular risk factors in surgically postmenopausal cynomolgus monkeys. Metabolism 1996;45:1254–62
18. Adams MR, Register TC, Golden DL, et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:217–21
19. Scarabin PY, Oger E, Plu-Bureau G., Estrogen and Thromboembolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428–32
20. Minkin MJ., Considerations in the choice of oral vs transdermal hormone therapy: a review. J Reprod Med 2004;49:311–20
21. Canonico M, Oger E, Plu-Bureau G, Estrogen and Thromboembolism Risk (ESTHER) Study Group, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840–5
22. Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30:340–5
23. Kannel WB, Hjortland MC, McNamara PM, Gordon T., Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 1976;85:447–52
24. Mikkola TS, Tuomikoski P, Lyytinen H, et al. Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy. J Clin Endocrinol Metab 2015;100:4588–94
25. Karim R, Dell RM, Greene DF, et al. Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause 2011;18:1172–7
26. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305–14
27. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013;310:1353–68
28. Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol 2012;120:595–603
29. Sarrel PM, Njike VY, Vinante V, Katz DL., The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59. Am J Public Health 2013;103:1583–8
30. Rivera CM, Grosshardt BR, Rhodes DY, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 2009;16:15–23
31. Parker WH, Feskanich D, Broder MS, et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol 2013;121:709–16
32. Salpeter SR, Cheng J, Thabane L, Buckley NS, Salpeter EE., Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med 2009;122:1016–22
33. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012;345:e6409
34. Savolainen-Peltonen H, Tuomikoski P, Korhonen P, et al. Cardiac death risk in relation to the age at Initiation or the Progestin Component of Hormone Therapies. J Clin Endocrinol Metab 2016;101:2794–801
35. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357–65
36. Manson JE, Allison MA, Rossouw JE, WHI and WHI-CACS Investigators, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007;356:2591–602
37. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006;55:103–15
38. Henderson VW, Paganini-Hill A, Emanuel CK, et al. Estrogen replacement therapy in older women: comparison between Alzheimer disease cases and nondemented control groups. Arch Neurol 1994;51:896–900
39. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet 1996;348:429–32
40. Kawas C, Resnick SM, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer disease: the Baltimore Longitudinal Study on Aging. Neurology 1997;48:1517–21
41. Waring SC, Rocca WA, Petersen RC, O’Brien PC, Tangalos EG, Kokmen E., Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology 1999;52:965–70
42. Steffens DC, Norton MC, Plassman BL, et al. Enhanced cognitive performance with estrogen use in nondemented community-dwelling older women. J Am Geriatr Soc 1999;47:1171–5
43. Kang JH, Weuve J, Grodstein F., Postmenopausal hormone therapy and risk of cognitive decline in community-dwelling aging women. Neurology 2004;63:101–7
44. Bechlioulis A, Kalantaridou SN, Naka KK, et al. Endothelial function, but not carotid intima-media thickness, is affected in early menopause and is associated with severity of hot flushes. J Clin Endocrinol Med 2010;95:1199–206
45. Gast GC, Grobee DE, Pop VJ, et al. Menopausal complaints are associated with CVD risk. Hypertension 2008;51:1492–8
46. Crandall CJ, Aragaki A, Cauley JA, et al. Association of vasomotor symptoms with fracture incidence. J Clin Endocrinol Med 2015;100:524–34
47. Challberg J, Ashcroft L, Lalloo F, et al. Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. Br J Cancer 2011;105:22–7
48. Thurston RC, Khoudary SR, Sutton-Tyrrell K, et al. Are vasomotor symptoms associated with alterations in hemostatic and inflammatory markers? Findings from the Study of Women’s Health Across the Nation. Menopause 2011;18:1044–51
49. Thurston RC, Aizenstein HJ, Derby CA, Sejdic E, Maki PM., Menopausal hot flashes and white matter hyperintensities. Menopause 2016;23:27–31
50. Worsley R, Bell R, Kulkarni J, Davis SR., The association between vasomotor symptoms and depression during perimenopause: a systematic review. Maturitas 2014;77:111–17
51. Silveira JS, Clapauch R, Souza M, Bouskela E., Hot flashes: emerging cardiovascular risk factors and their association with higher blood pressure. Menopause 2016;23:846–55
52. Ratka A., Menopausal hot flashes and development of cognitive impairment. Ann N Y Acad Sci 2005;1052:11–26
53. Asante A, Whiteman MK, Kulkarni A, Cox S, Marchbanks PA, Jamieson DJ. Elective oophorectomy in the United States: trends and in-hospital complications, 1998-2006. Obstet Gynecol 2010;116:1088–95
54. Wright JD, Herzog TJ, Tsui J, et al. Nationwide trends in the performance of hysterectomy in the United States. Obstet Gynecol 2013;122:233–41
55. United States Census Bureau. Profile of general population and housing characteristics: 2010 demographic profile data.
56. Rocca WA, Gazzuola-Rocca L, Smith CY, et al. Accelerated accumulation of multimorbidity after bilateral oophorectomy: a population-based cohort study. Mayo Clin Proc 2016;91:1577–89
57. Bove R, Secor E, Chibnik LB, et al. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology 2014;82:222–9
58. Lokkegaard E, Jovanovic Z, Heitmann BL, Kelding N, Ottesen B, Pedersen AT., The association between early menopause and risk of ischaemic heart disease: influence of hormone therapy. Maturitas 2006;53:226–33
59. Dorum A, Tonstad S, Liavaag AH, Michelsen TM, Hildrum D, Dahl AA., Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: a controlled, population-based study (HUNT-2). Gynecol Oncol 2008;109:377–83
60. Yoshida T, Takahashi K, Yamatani H, Takata K, Kurachi H., Impact of surgical menopause on lipid and bone metabolism. Climacteric 2011;14:445–52
61. Fournier A, Berrino F, Riboli E, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005;114:448–54
62. Fournier A, Berrino F, Clavel-Chapelon F., Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103–11
63. Wood CE, Register TC, Lees CJ, et al. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat 2007;101:125–34
64. Manson JE, Hsia J, Johnson KC, for the Women's Health Initiative Investigators, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523–34
65. Toh S, Hernández-Díaz S, Logan R, et al. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med 2010;152:211–17
66. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605–13
67. Barrett-Connor E, Bush TL., Estrogen and coronary heart disease in women. JAMA 1991;265:1861–7
68. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016–37
69. Langer RD., The evidence base for HRT: what can we believe? Climacteric 2017;20:91–6
70. Santen RJ., Menopausal hormone therapy and breast cancer. J Steroid Biochem Mol Biol 2014;142:52–61
71. Prentice RL, Caan B, Chlebowski RT, et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006;295:629–42
72. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33
73. Henderson VW, St John JA, Hodis HN, et al. Cognitive effects of estradiol after menopause: a randomized trial of the timing hypothesis. Neurology 2016;87:699–708
74. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003;290:1729–38
75. Jackson RD, Wactawski-Wende J, LaCroix AZ, et al. Effects of conjugated equine estrogen on risk of fractures, and BMD in postmenopausal women with hysterectomy: results from the Women’s Health Initiative randomized trial. J Bone Miner Res 2006;21:817–28
76. Zhu L, Jiang X, Sun Y, Shu W., Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis of randomized controlled trials. Menopause 2016;23:461–70
77. Benhamou CL., Effects of osteoporosis medications on bone quality. Joint Bone Spine 2007;74:39–47
78. Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women. A randomized trial. Ann Intern Med 2014;161:249–60
79. Pereira RI, Casey BA, Swibas TA, et al. Timing of estradiol treatment after menopause may determine benefit or harm to insulin action. J Clin Endocrinol Metab 2015;100:4456–62
80. Mauvais-Jarvis F, Manson JE, Stevenson JC, Fonseca VA., Menopausal hormone therapy and type 2 diabetes prevention: evidence, mechanisms and clinical implications. Endocr Rev 2017;38:173–88
81. Palma F, Volpe A, Villa P, Cagnacci A., Writing Group of AGATA study. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: the AGATA study. Maturitas 2016;83:40–4
82. Kingsberg SA, Wysocki S, Magnus L, Krychman ML., Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s Views of Treatment Options for Menopausal Vaginal ChangEs) Survey. J Sex Med 2013;10:1790–9
83. Pinkerton JV, Bushmakin AG, Komm BS, Abraham L., Relationship between changes in vulvar-vaginal atrophy and changes in sexual functioning. Maturitas 2017;100:57–63
84. Willhite LA, O’Connell MB., Urogenital atrophy: prevention and treatment. Pharmacotherapy 2001;21:464–80
85. Grodstein F, Newcomb PA, Stampfer MJ., Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999;106:574–82
86. Prentice RL, Pettinger M, Beresford SA, et al. Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women's Health Initiative clinical trial and observational study. Cancer Epidemiol Biomarkers Prev 2009;18:1531–7
87. The Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
88. Williams C, DiLeo A, Niv Y, Gustafsson JA., Estrogen receptor beta as target for colorectal cancer prevention. Cancer Lett 2016;372:48–56
89. Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015;CD002229
90. Lobo RA, Pickar JH, Stevenson JC, Mack WJ, Hodis HN., Back to the future: hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. Atherosclerosis 2016;254:282–90
91. Mikkola TS, Tuomikoski P, Lyytinen H, et al. Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopause 2015;22:976–83
92. Maruther NM., Interventions to reduce coronary artery disease risk. Results from the PREMIER trial. Circulation 2009;119:2026–31
93. Lobo RA, Davis SR, de Villiers TJ, et al. Prevention of diseases after menopause. Climacteric 2014;17:540–56
94. Walsh JM, Pignone M., Drug treatment of hyperlipidemia in women. JAMA 2004;291:2243–52
95. Petretta M, Costanzo P, Perrone-Filardi P., Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis. Int J Cardiol 2010;138:25–31
96. Brugts JJ, Yetkin T, Hoeks SE., The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomized controlled trials. BMJ 2009;338:b2376
97. Berger JS, Roncaglioni C, Avanzini F., Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295:306–13
98. Ridker PM, Cook NR, Lee IM., A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293–304
99. Ogawa H, Nakayama M, Morimoto T., Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300:2134–41
100. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:725–42
101. Mora S, Glynn RJ, Hsia J, et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010;121:1069–77
102. Hodis HN, Mack WJ. The timing hypothesis and hormone replacement therapy: a paradigm shift in the primary prevention of coronary heart disease in women. Part 2: comparative risks. J Am Geriatr Soc 2013;61:1011–18
103. U.S. Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: preventive medication. Release Date: November 2016. Available from: https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummary Final/statin-use-in-adults-preventive-medication